Items where authors include "Holland, TL"

Export as [feed] Atom [feed] RSS
Jump to: Article
Number of items: 5.

Article

Noviello, S, Corey, GR, Holland, TL et al. (9 more authors) (2020) A pooled analysis of patients with wound infections in the Phase 3 REVIVE trials: randomized, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections. Journal of Medical Microbiology. 001177. ISSN 0022-2615

Huang, DB, Magnet, S, De Angelis, S et al. (6 more authors) (2019) Surveillance of iclaprim activity: in vitro susceptibility of Gram-positive skin infection pathogens collected from 2015 to 2016 from North America and Europe. Diagnostic Microbiology and Infectious Disease, 93 (2). ISSN 0732-8893

Huang, DB, Corey, GR, Holland, TL et al. (8 more authors) (2018) Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections. International Journal of Antimicrobial Agents, 52 (2). pp. 233-240. ISSN 0924-8579

Holland, TL, O'Riordan, W, McManus, A et al. (12 more authors) (2018) A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study). Antimicrobial Agents and Chemotherapy, 62 (5). e02580-17. ISSN 0066-4804

Huang, DB, O'Riordan, W, Overcash, JS et al. (10 more authors) (2018) A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1. Clinical Infectious Diseases, 66 (8). pp. 1222-1229. ISSN 1058-4838

This list was generated on Sat Apr 13 21:19:19 2024 BST.